Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Harvard Business School
Mallinckrodt
McKesson
Dow

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

PEXEVA Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Pexeva patents expire, and what generic alternatives are available?

Pexeva is a drug marketed by Sebela Ireland Ltd and is included in one NDA. There is one patent protecting this drug.

This drug has forty patent family members in twenty-five countries.

The generic ingredient in PEXEVA is paroxetine mesylate. There are thirty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the paroxetine mesylate profile page.

Drug patent expirations by year for PEXEVA
Drug Prices for PEXEVA

See drug prices for PEXEVA

Drug Sales Revenue Trends for PEXEVA

See drug sales revenues for PEXEVA

Recent Clinical Trials for PEXEVA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Central Michigan UniversityN/A
Sheppard Pratt Health SystemN/A

See all PEXEVA clinical trials

Recent Litigation for PEXEVA

Identify potential future generic entrants

District Court Litigation
Case NameDate
SEBELA INTERNATIONAL LIMITED v. PRINSTON PHARMACEUTICAL, INC.2017-07-06
IN RE SEBELA PATENT LITIGATION2014-10-16
Valeant International, Bermuda v. Watson Pharmaceuticals Inc.2010-02-19

See all PEXEVA litigation

Pharmacology for PEXEVA
Synonyms for PEXEVA
(-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine
(-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-methylenedioxy)phenoxy)methyl)piperidine
(-)-Paroxetine
(-)-trans-4-(4-Fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)piperidine
(-)-trans-4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl]-piperidine
(3S-trans)-3-[(1,3-Benzodioxol-5-yl-oxy)methyl]-4-(4-fluorophenyl)piperidine
(3s,4r)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine
(3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine
(3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine
(3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine
[3H]Paroxetine
110429-35-1
110429-35-1 (HCl hemihydrate)
3-(Benzo[1,3]Dioxol-5-Yl-Oxymethyl)-4-(4-Fluoro-Phenyl)-Piperidine Hydrochloride
3h-paroxetine
41VRH5220H
61869-08-7
63952-24-9
64006-44-6 (maleate)
72471-80-8 (acetate)
78246-49-8 (hydrochloride)
869P087
8PR
AB00053704_22
AB00053704_23
AB00053704-21
AB00514724
AC-8185
AC1L2AKL
AC1Q1H18
AC1Q4LV6
AHOUBRCZNHFOSL-YOEHRIQHSA-N
AJ-23329
AK501459
AKOS015888636
AN-8247
Aropax
BDBM22416
BDBM50331515
BIDD:GT0673
BPBio1_000949
BRD-K37991163-003-02-7
BRD-K37991163-050-05-1
BRL 29060
BRL-29060
BSPBio_000861
C-19975
C07415
C19H20FNO3
CAS-61869-08-7
Casbol
CC-33477
CHEBI:7936
CHEMBL1708
CHEMBL490
D02362
DB00715
DivK1c_006884
DSSTox_CID_3425
DSSTox_GSID_23425
DSSTox_RID_77022
DTXSID3023425
FG 7051
FG-7051
Frosinor
FT-0085087
GTPL4790
HMS2090H05
HSDB 7175
I14-7752
KB-277026
KB-302613
KBio1_001828
KBio2_002232
KBio2_004800
KBio2_007368
KBioSS_002232
KS-00000JK2
LS-114249
MolPort-003-849-791
Motivan
NCGC00025355-02
NCGC00025355-03
NCGC00025355-04
NCGC00025355-05
NCGC00025355-06
NCGC00025355-07
NCGC00025355-08
NCGC00025355-09
NCGC00025355-12
NCGC00182968-01
NNC-20-7051
Paroxetin HCL
Paroxetina
Paroxetina [INN-Spanish]
paroxetine
Paroxetine (TN)
Paroxetine (USP/INN)
Paroxetine [USAN:INN:BAN]
Paroxetine Acetate
PAROXETINE HCL HEMIHYDRATE
paroxetine hydrochloride (anhydrous or hemihydrate)
Paroxetine.HCl
Paroxetinum
Paroxetinum [INN-Latin]
Paxetil
Paxil
Paxil CR
Paxil, Pexeva
PaxPar
Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3S-trans)-
Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3S,4R)-
Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S-trans)-
piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S,4R)-
Piperidine,3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S,4R)-
Piperidine,3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-,(3S,4R)-
Prestwick3_000851
SBI-0051908.P002
SC-16100
SC-22977
SCHEMBL27799
Seroxat
Seroxat CR
SpecPlus_000788
Spectrum_001752
Spectrum5_001665
TL8003967
Tox21_113123
Tox21_113123_1
UNII-41VRH5220H
ZINC527386

US Patents and Regulatory Information for PEXEVA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-001 Jul 3, 2003 RX Yes No   Start Trial   Start Trial Y   Start Trial
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-004 Jul 3, 2003 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-002 Jul 3, 2003 RX Yes No   Start Trial   Start Trial Y   Start Trial
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-003 Jul 3, 2003 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PEXEVA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-001 Jul 3, 2003   Start Trial   Start Trial
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-003 Jul 3, 2003   Start Trial   Start Trial
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-004 Jul 3, 2003   Start Trial   Start Trial
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-002 Jul 3, 2003   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Johnson and Johnson
McKesson
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.